HOME >> MEDICINE >> NEWS
ARICEPT significantly improves cognition, daily living over Reminyl in Alzheimers patients

GENEVA, SWITZERLAND (4 APRIL 2002) - Results from the first head-to-head study comparing ARICEPT (donepezil HCl tablets) and Reminyl (galantamine HBr tablets) demonstrated significantly greater improvements in cognition and activities of daily living (ADLs) in mild to moderate Alzheimer's disease (AD) patients treated with ARICEPT vs. Reminyl. ARICEPT-treated patients showed significant benefit over patients receiving Reminyl as measured by the modified 13-item Alzheimer's Disease Assessment Scale-cognitive subscale (modified ADAS-cog), achieved significant improvements on the Mini-Mental State Examination (MMSE), and had significantly greater improvements in ADLs, as measured by the Disability Assessment for Dementia (DAD) scale total score. The study was primarily designed to evaluate safety and tolerability. The first-ever presentation of these data took place at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (AAT) in Geneva, Switzerland.

"By comparing two available Alzheimer's disease medications, physicians now have clinical evidence that will help them prescribe the most appropriate treatment for their patients," said study investigator Roy Jones, MD, Research Institute for the Care of the Elderly, St Martin's Hospital, Bath, United Kingdom. "This three month study is encouraging news for mild to moderate Alzheimer's disease patients currently on ARICEPT, as well as those who have yet to initiate treatment." The 12-week, multinational (United Kingdom, Finland, Norway and Germany), head-to-head, randomized open-label study was designed primarily to evaluate the safety and tolerability of ARICEPT (n= 64) and Reminyl (n= 56) in 120 patients with possible or probable mild to moderate Alzheimer's disease. The study also investigated the effects of both treatments on cognition and ADLs, such as meal preparation and finance and correspondence. Trained raters who were blinded to study medication and trial results admin
'"/>


4-Apr-2002


Page: 1 2 3 4

Related medicine news :

1. First-of-its-kind study of vascular dementia patients taking ARICEPT presented at AAGP meeting
2. Vascular dementia patients taking ARICEPT show significant treatment benefits in cognition and function
3. ARICEPT better tolerated than Exelon in patients with mild to moderate Alzheimers disease
4. Moving admitted ER patients into inpatient beds faster could significantly increase hospital revenue
5. Gastrointestinal disorders are associated significantly with sleepless nights
6. Landmark survey reveals asthma in children remains significantly out of control in the United States
7. Data suggest ADDERALL XR significantly improved simulated driving in young adults with ADHD
8. Elderly cancer patients are significantly under-represented in cancer clinical trials
9. Generic anti-inflammatory causes significantly fewer GI complications than branded medications
10. Study shows weight-based REBETOL dosing in combination with PEG-INTRON significantly improves ...
11. Radiotherapy + cetuximab significantly improve disease control and survival in head and neck cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with ... for the primary prevention of cardiovascular diseases during the 15th Annual Women’s ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/22/2017)... DIEGO , Sept. 22, 2017 AVACEN ... medical device is now successfully helping those with the ... Fibromyalgia diagnosed Amanda in Essex, ... dressed and washing my hair, experiencing no sleep at ... in painful spasm… I cannot recommend [the AVACEN 100] ...
Breaking Medicine Technology:
Cached News: